2022-08 – Q2 2022 Reporting
Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…
Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…
AGM 2022 to be postponed until late june 2022 Read more
Highlights SER150 clinical study in Australia is still delayed after Covid19 lockdownsSerodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.The Group qualified for and received a “Patent…
Announcement Release SER150 CL-009 Approval EC AustraliaDownload
Subscription Period to be extended until the 12th of May: Read more
Link Serodus Prospectus: Read more